Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02062957
Other study ID # NF81300148
Secondary ID
Status Recruiting
Phase N/A
First received February 11, 2014
Last updated February 23, 2014
Start date February 2014

Study information

Verified date February 2014
Source Beijing Chao Yang Hospital
Contact n/a
Is FDA regulated No
Health authority China: Beijing Municipal Science and Technology Commission
Study type Observational

Clinical Trial Summary

1. recruit 50 patients with atrial fibrillation and 30 controls

2. endovascular function assessment with Peripheral Arterial Tonometry (PAT)

3. follow up the occurence of AF


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date
Est. primary completion date July 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- =2 paroxysmal (electrocardiographic documentation of at least 1) AF episodes lasting =1 hour in duration: (that terminate spontaneously within 7 days or cardioversion is performed within 48h of AF onset): or

- electrocardiographic documentation of 1 persistent AF episode: (sustained for =7 days or cardioversion is performed more than 48h after AF onset): or

- electrocardiographic documentation of 1 longstanding persistent AF episode: (continuous AF of duration >1 year).

Exclusion Criteria:

- patients with cerebralvascular disease

- patients with coronary disease

- patients with peripheric artery disease

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
China Beijing Chaoyang Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Chao Yang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary endovascular function results The method to assess the endovascular function is PAT. The index is Reactive hyperemia index (RHI). RHI between patients and control will be compared. Up to 24 weeks. No
Secondary predictive effect of endovascular function on recurrence of AF We will do the multi-logistic analysis of the recurrence of AF. Up to 1 year No